Orchid Pharma Limited — PPTs, 12-08-2025: Investor Presentation

**Financial Highlights:**

Orchid Pharma's Q1 FY26 financials show a notable decline. Sales were down 29% YoY to 173 Cr. EBITDA dropped 27% to 30 Cr, with PBT and PAT each falling 38% to 18 Cr. Despite the sales decrease, EBITDA margin held steady at 17%, and Gross Margin improved to 43% from 39%. For the full FY25, sales grew 13% and PAT increased 12%.

**Strategic Initiatives & Growth Drivers:**

The presentation did not detail any strategic initiatives, new launches, or expansion plans.

**Business Developments:**

No information on recent acquisitions, partnerships, or product rollouts was provided.

**Market Position & Competitive Advantage:**

The document offered no commentary on the company's market position, differentiation, or competitive advantages.

**Investor Implications:**

The significant Q1 FY26 downturn in revenue and profit marks a challenging start to the fiscal year, contrasting with FY25's growth. Investors should monitor future quarters for recovery, indicating potential execution risk.